RYZNEUTA
There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, pegfilgrastim administration during organogenesis caused increased post-implantation loss, decreased fetal weight, and structural abnormalities. RYZNEUTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
